FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118429250> ?p ?o ?g. }

• W2118429250 endingPage "F1333" @default.
• W2118429250 startingPage "F1323" @default.
• W2118429250 abstract "Aldosterone (Aldo) stimulates glomerular mesangial cell (MC) proliferation, in part, through an ERK1/2-dependent pathway. In this study, we examined whether Aldo activation of ERK1/2 in MC is mediated through redox-dependent EGF receptor (EGFR) transactivation, as well as the involvement of other signaling mechanisms in Aldo-induced MC proliferation. Aldo increased human MC proliferation, as determined by [(3)H]thymidine incorporation and cell counts. This increase in proliferation was blocked by inhibition of the mineralocorticoid receptor (MR). Continuing our observations downstream in the signaling pathway, we examined the ability of Aldo to activate both the Ras/MAPK and the PI3K signaling pathways. Aldo increased Ki-RasA and Ki-RasA:GTP levels, and sequentially phosphorylated c-Raf, MAPK kinase (MEK1/2), and ERK1/2. Ki-RasA small interfering RNA (siRNA), the c-Raf inhibitor GW5074, and the MEK1/2 inhibitor PD98059 reduced Aldo-induced cell proliferation by approximately 65%. Aldo also increased phosphorylation of PI3K, Akt, the mammalian target of rapamycin (mTOR), and the 70-kDa ribosomal S6 kinase (p70S6K1). Inhibition of the PI3K pathways by the selective PI3K inhibitor LY 294002, an Akt inhibitor, or the mTOR inhibitor rapamycin reduced cell proliferation by 51%. Combining LY 294002 and PD98059 completely blocked Aldo-induced MC proliferation. Next, we confirmed that Aldo exerts its effect on MAPK and PI3K activation, as well as on cell proliferation, by activating the EGFR. Pretreatment with the EGFR antagonist AG1478 inhibited MC proliferation, as well as the activation of Ras/MAPK and PI3K/Akt, suggesting that Ras/MAPK and PI3K/Akt activation occur downstream of EGFR activation. Finally, we examined the role of reactive oxygen species (ROS) in Aldo-induced transactivation of the EGFR. Aldo-induced ROS were predominantly generated by mitochondria. Pretreatment with the antioxidant N-acetyl-l-cysteine, catalase, SOD, mitochondrial respiratory chain complex I inhibitor rotenone (Rot), NADPH oxidase inhibitor apocynin, and DPI significantly inhibited Aldo-stimulated MC proliferation as well as EGFR transactivation. However, Rot reduced MC proliferation more potently than apocynin and DPI. In conclusion, Aldo stimulated cell proliferation through MR-mediated, redox-sensitive EGFR transactivation, which was dependent on the Ki-RasA/c-Raf/MEK/ERK and PI3K/Akt/mTOR/p70S6K1 signaling pathways in human MCs." @default.
• W2118429250 created "2016-06-24" @default.
• W2118429250 creator A5028277558 @default.
• W2118429250 creator A5041999576 @default.
• W2118429250 creator A5048761144 @default.
• W2118429250 creator A5054380056 @default.
• W2118429250 date "2009-06-01" @default.
• W2118429250 modified "2023-10-08" @default.
• W2118429250 title "Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation" @default.
• W2118429250 cites W1585517331 @default.
• W2118429250 cites W1963723155 @default.
• W2118429250 cites W1967432915 @default.
• W2118429250 cites W1970209851 @default.
• W2118429250 cites W1971098577 @default.
• W2118429250 cites W1973794764 @default.
• W2118429250 cites W1981409666 @default.
• W2118429250 cites W1988361026 @default.
• W2118429250 cites W1989708376 @default.
• W2118429250 cites W1993984639 @default.
• W2118429250 cites W1994623583 @default.
• W2118429250 cites W1995829325 @default.
• W2118429250 cites W2000060059 @default.
• W2118429250 cites W2002087415 @default.
• W2118429250 cites W2005529016 @default.
• W2118429250 cites W2006439578 @default.
• W2118429250 cites W2035016947 @default.
• W2118429250 cites W2036956805 @default.
• W2118429250 cites W2055592943 @default.
• W2118429250 cites W2057106513 @default.
• W2118429250 cites W2061951501 @default.
• W2118429250 cites W2066254967 @default.
• W2118429250 cites W2071463401 @default.
• W2118429250 cites W2074149689 @default.
• W2118429250 cites W2075992471 @default.
• W2118429250 cites W2086930111 @default.
• W2118429250 cites W2087904403 @default.
• W2118429250 cites W2094703210 @default.
• W2118429250 cites W2096645292 @default.
• W2118429250 cites W2107418117 @default.
• W2118429250 cites W2109888686 @default.
• W2118429250 cites W2116163401 @default.
• W2118429250 cites W2120573367 @default.
• W2118429250 cites W2126174661 @default.
• W2118429250 cites W2133150758 @default.
• W2118429250 cites W2133203551 @default.
• W2118429250 cites W2137628287 @default.
• W2118429250 cites W2138366753 @default.
• W2118429250 cites W2153347595 @default.
• W2118429250 cites W2156138425 @default.
• W2118429250 cites W2168779696 @default.
• W2118429250 cites W2314235576 @default.
• W2118429250 cites W2418646186 @default.
• W2118429250 cites W4240242550 @default.
• W2118429250 cites W4292820908 @default.
• W2118429250 cites W67399661 @default.
• W2118429250 doi "https://doi.org/10.1152/ajprenal.90428.2008" @default.
• W2118429250 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19339632" @default.
• W2118429250 hasPublicationYear "2009" @default.
• W2118429250 type Work @default.
• W2118429250 sameAs 2118429250 @default.
• W2118429250 citedByCount "82" @default.
• W2118429250 countsByYear W21184292502012 @default.
• W2118429250 countsByYear W21184292502013 @default.
• W2118429250 countsByYear W21184292502014 @default.
• W2118429250 countsByYear W21184292502015 @default.
• W2118429250 countsByYear W21184292502016 @default.
• W2118429250 countsByYear W21184292502017 @default.
• W2118429250 countsByYear W21184292502018 @default.
• W2118429250 countsByYear W21184292502019 @default.
• W2118429250 countsByYear W21184292502020 @default.
• W2118429250 countsByYear W21184292502021 @default.
• W2118429250 countsByYear W21184292502022 @default.
• W2118429250 countsByYear W21184292502023 @default.
• W2118429250 crossrefType "journal-article" @default.
• W2118429250 hasAuthorship W2118429250A5028277558 @default.
• W2118429250 hasAuthorship W2118429250A5041999576 @default.
• W2118429250 hasAuthorship W2118429250A5048761144 @default.
• W2118429250 hasAuthorship W2118429250A5054380056 @default.
• W2118429250 hasConcept C104202773 @default.
• W2118429250 hasConcept C104317684 @default.
• W2118429250 hasConcept C11960822 @default.
• W2118429250 hasConcept C1292079 @default.
• W2118429250 hasConcept C153911025 @default.
• W2118429250 hasConcept C184235292 @default.
• W2118429250 hasConcept C185592680 @default.
• W2118429250 hasConcept C2780044377 @default.
• W2118429250 hasConcept C2780926556 @default.
• W2118429250 hasConcept C502942594 @default.
• W2118429250 hasConcept C55493867 @default.
• W2118429250 hasConcept C57074206 @default.
• W2118429250 hasConcept C62112901 @default.
• W2118429250 hasConcept C62478195 @default.
• W2118429250 hasConcept C75217442 @default.
• W2118429250 hasConcept C86339819 @default.
• W2118429250 hasConcept C86554907 @default.
• W2118429250 hasConcept C86803240 @default.
• W2118429250 hasConcept C95444343 @default.
• W2118429250 hasConceptScore W2118429250C104202773 @default.

• next